Business Segments · Royalty Expense
Business Segments — Royalty Expense
Amgen Business Segments — Royalty Expense decreased by 1.7% to $564.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 28.2%, from $440.00M to $564.00M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalLower is better
VolatilityModerate
First reportedQ1 2024
Last reportedQ1 2026
How to read this metric
Higher expenses may indicate reliance on external innovation, while lower expenses suggest a higher proportion of internally developed intellectual property.
Detailed definition
Represents payments made to third parties for the use of intellectual property, patents, or licensed technologies incorp...
Peer comparison
Standard for biotech firms that license drug candidates or platform technologies from academic institutions or smaller peers.
Metric ID:
amgn_segment_reportable_segment_royalty_expenseHistorical Data
7 periods
| Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|
| Value | $386.00M | $411.00M | $458.00M | $440.00M | $527.00M | $574.00M | $564.00M |
| QoQ Change | — | +6.5% | +11.4% | -3.9% | +19.8% | +8.9% | -1.7% |
| YoY Change | — | — | — | +14.0% | +28.2% | +25.3% | +28.2% |
Range$386.00M – $574.00M
CAGR+28.8%
Avg YoY Growth+23.9%
Median YoY Growth+26.8%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's business segments — royalty expense?
- Amgen (AMGN) reported business segments — royalty expense of $564.00M in Q1 2026.
- How has Amgen's business segments — royalty expense changed year-over-year?
- Amgen's business segments — royalty expense increased by 28.2% year-over-year, from $440.00M to $564.00M.
- What does business segments — royalty expense mean?
- Payments made to others for the right to use their technology or patents in the company's products.